MAPT and Alzheimer disease: Although recent investigation of blood-based biomarkers has demonstrated differences between plasma concentration of phosphorylated tau in DLB and AD cohorts, neither demonstrated diagnostic accuracy for p-tau181 (AUC = 0.62–0.67) or p-tau231 (AUC = 0.56) supportive of their use as a biomarker (Chouliaras et al., 2022; Gonzalez et al., 2022).